Gene therapy for hematological malignancies

Clinical and Experimental Medicine

Volumn 3, Issue 1, 2003, Pages 4-14

  Schmidt Wolf, G D ^a   Schmidt Wolf, I G H ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Clinical trials; Gene therapy; Hematological malignancies; Review

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; CELL ADHESION MOLECULE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE RELEASING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; ONCOLYTIC VIRUS; TUMOR VACCINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; LEUKEMIA; LYMPHOMA; MARKER GENE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUICIDE GENE THERAPY; TELOMERE; TREATMENT PLANNING;

APOPTOSIS; CANCER VACCINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 0038020055     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s102380300009     Document Type: Review

References (88)

1. Wu Q, Moyana T, Xiang J (2001) Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther 1:101-122
2. Reid T, Warren R, Kirn D (2002) Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9:979-986
3. Kaiser J (2003) Seeking the cause of induced leukemias in X-SCID trial. Science 299:495
4. Schmidt-Wolf G, Schmidt-Wolf I (2003) Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med (in press)
5. Kume A, Hanazono Y, Mizukami H, Okada T, Ozawa K (2002) Selective expansion of transduced cells for hematopoietic stem cell gene therapy. Int J Hematol 76:299-304
6. Licht T, Peschel C (2002) Restoration of transgene expression in hematopoietic cells with drug-selectable marker genes. Curr Gene Ther 2:227-234
7. Richter J, Karlsson S (2001) Clinical gene therapy in hematology: past and future. Int J Hematol 73:162-169
8. Litvinova E, Maury S, Boyer O, Bruel S, Benard L, Boisserie G, Klatzmann D, Cohen JL (2002) Graft-versus-leukemia effect after suicide-gene-mediated controlling of graft-versus-host disease. Blood 100:2020-2025
9. Garin MI, Garrett E, Tiberghien P, Apperley JF, Chalmers D, Melo, Ferrand C (2001) Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97:122-129
10. Verzeletti S, Bonini C, Marktel S, Nobili N, Ciceri F, Traversari C, Bordignon C (1998) Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 9:2243-2251
11. Anderson WF (1998) Human gene therapy. Nature 392:25-30
12. Brenner MK (2001) Gene transfer and the treatment of haematological malignancy. J Int Med 249:345-358
13. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brenner MK (1999) Autoimmune disease induced by dendritic cell immunization against leukemia. Leukemia Res 23:549-557
14. Wivel NA, Wilson JM (1998) Methods of gene delivery. Hematol Oncol Clin North Am 12:483-501
15. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, Brenner M (1996) Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 2:1090
16. Wang R-F, Rosenberg SA (1999) Human tumor antigens for cancer vaccine development. Immunol Rev 170:85-100
17. Bronte V (2001) Genetic vaccination for the active immunotherapy of cancer. Curr Gene Ther 1:53-100
18. Reinhard G, Märten A, Kiske M, Feil F, Bieber T, Schmidt-Wolf IGH (2001) Generation of dendritic-cell based vaccines for cancer gene therapy. Br J Cancer 86:1529-1533
19. Märten A, Ziske C, Schöttker B, Weineck S, Renoth S, Buttgereit P, Schakowski F, König S, Rucker Avon, Allera A, Schroers R, Sauerbruch T, Wittig B, Schmidt-Wolf IG (2001) Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs. Cancer Gene Ther 8:211-219
20. Lotze MT, Shurin M, Esche C, Tahara H, Storkus W, Kirkwood JM, Whiteside TL, Elder EM, Okada H, Robins P (2000) Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J 6:S61-S66
21. Yee C, Riddell SR, Greenberg PD (1997) Prospects for adoptive T cell therapy. Curr Opin Immunol 9:702-708
22. Falkenburg JHF, Smit WM, Willemze R (1997) Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloic leukemia. Immunol Rev 157:223-230
23. Rooney CM, Smith CA, Ng C, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9-13
24. Brenner MK (1998) Applications of gene transfer in hematologic malignancy. Recent Results Cancer Res 144:61-69
25. Ettinghausen SE, Rosenberg SA (1995) Immunotherapy and gene therapy of cancer. Adv Surg 28:223-254
26. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118-1122
27. Mc Guiness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, Schlom J, Finer MH, McArthur JG (1999) Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 10:165-173
28. Schumacher TN (2002) T-cell-receptor gene therapy. Nat Rev Immunol 2:512-519
29. Schmidt-Wolf IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D (1999) Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81:1009-1016
30. Wittig B, Märten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Löffel J, Albers P, Müller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IGH (2001) Therapeutic vaccination against metastatic carcinoma by expression-modulated and immuno-modified autologous tumor cells: a first clinical phase/II trial. Hum Gene Ther 12:267-278
31. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Habib NA et al. (1999) Human gene marker/therapy clinical protocols. Hum Gene Ther 10:3067-3123
32. Agha-Mohammadi S, Lotze MT (2000) Regulatable systems: applications in gene therapy and replicating viruses. J Clin Invest 105:1177-1182
33. Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Steward AK (2001) Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 8:361-370
34. Warren TL, Weiner GJ (2000) Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 7:168-173
35. Schmidt-Wolf GD, Schmidt-Wolf IGH (2002) Immunomodulatory gene therapy for haematological malignancies. Br J Haematol 117:23-32
36. Nemunaitis J, Cunningham C (2002) Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. Drug Resist Updat 5:34-46
37. Piche A, Rancourt C (2001) Gene therapy to overcome drug resistance in cancer: targeting key regulators of the apoptotic pathway. Curr Gene Ther 1:317-324
38. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A (2003) Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 8:67-77
39. Hobin DA, Fairbairn LJ (2002) Genetic chemoprotection with mutant O6-alkylguanine- DNA-alkyltransferases. Curr Gene Ther 2:1-8
40. Sorrentino BP (2002) Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2:431-441
41. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP (1996) A gene transfer strategy for making bone-marrow cells resistant to trimetrexate. Blood 87:2579-2587
42. Banerjee D, Bertino JR (2002) Myeloprotection with drug-resistance genes. Lancet Oncol 3:154-158
43. Donahue JM, Mullen JT, Tanabe KK (2002) Viral oncolysis. Surg Oncol Clin North Am 11:661-680
44. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ (2001) Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98:2002-2007
45. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK (2001) Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97:3746-3754
46. Coffey MC, Strong JE, Forsyth PA, Lee PWK (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334
47. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PWK, Kossakowska AE (2002) Blood 100:4146-4153
48. Yan W, Kitzes G, Dormishian F, Hawkins L, Sampson-Johannes A, Watanabe J, Holt J, Lee V, Dubensky T, Fattaey A, Hermiston T, Ba A, Shen Y (2003) Developing novel oncolytic adenoviruses through bioselection. J Virol 77:2640-2650
49. Bell JC, Garson KA, Lichty BD, Stojdl DF (2002) Oncolytic viruses: programmable tumour hunters. Curr Gene Ther 2:243-254
50. Ring CJ (2002) Cytolytic viruses as potential anti-cancer agents. J Gen Virol 83:491-502
51. Rawstron AC, Barrans SI, Blythe D, Davies FE, English A, Pratt G, Child JA, Jack AS, Morgan GJ (1999) Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 104:138-143
52. Brenner MK (1997) Emerging applications of gene transfer in hematopoietic cancers. J Pediatr Hematol Oncol 19:1-6
53. Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20:3906-3927
54. Vacca A, Ribatti D, Presta M, Minischetti M, Lurlaro M, Ria R, Albini A, Bussolino F, Dammaco F (1999) Bone marrow neovascularisation, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-3073
55. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Grieff PR (1999) Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13:469-472
56. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I, Knox RJ, Plumb JA, Keith WN (2003) Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22:370-380
57. Yamada K, Yagihashi A, Yamada M, Asanuma K, Moriai R, Kobaya D, Tsuji N, Watanabe N (2002) Decreased gene expression for telomeric-repeat binding factors TRF and TIN2 in malignant hematopoietic cells. Anticancer Res 22:1315-1320
58. Watanabe T, Sullenger BA (2000) Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci U S A 97:8490-8494
59. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
60. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011-1017
61. Su Z, Peluso MV, Raffegerst SH, Schendel DJ, Roskrow MA (2001) The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 31:947-958
62. Sullenger BA, Gilboa E (2002) Emerging clinical applications of RNA. Nature 418:252-258
63. Draghia-Akli R, Hahn KA, King GK, Cummings KK, Carpenter RH (2002) Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol Ther 6:830-836
64. Lim SH, Coleman S (1997) Chronic myeloid leukemia as an immunological target. Am J Hematol 54:61-67
65. Kipps TJ (1999) Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. Semin Hematol 36:3-8
66. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M (1999) CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 93:1992-2002
67. Kipps TJ (2002) Immune and cell therapy of hematologic malignancies. Int J Hematol 76:269-273
68. Kipps TJ, Chu P, Wierda WG (2000) Immunogenetic therapy for B-cell malignancies. Semin Oncol 27:104-109
69. Borgmann A, von Stackelberg A, Baumgarten E, Uchanska-Ziegler B, Ziegler A, Wittig B, Henze G (1998) Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment. J Mol Med 76:215-221
70. Smith ML, Newland AC (1999) Treatment of myeloma. Q J Med 92:11-14
71. Van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, Andre M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, Boon T (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94:1156-1164
72. Bjorkstrand B, Dilber MS, Smith CI, Gahrton G, Xanthopoulos KG (1994) Retroviral-mediated gene transfer into human myeloma cells. Br J Haematol 88:325-331
73. Drach J, Kaufmann H (2002) New developments and treatment in multiple myeloma: new insights on molecular biology. Ann Oncol 13:43-47
74. Kopantzev E, Roschke V, Rudikoff S (1998) Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma. Hum Gene Ther 9:13-19
75. Trudel S, Li Z, Dodgson C, Nanji S, Wan Y, Voralia M, Hitt M, Gauldie J, Graham FL, Stewart AK (2001) Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study. Leukemia 15:846-854
76. Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H (1998) Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther 9:1121-1130
77. Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H (1999) Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 93:1831-1837
78. Li ZH, Mandelbaum S, Hawley T, Hawley RG, Steward AK (1999) Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma. Blood 94:2679
79. Wendtner CM, Nolte A, Mangold E, Buhmann R, Maass G, Chiorini JA, Winnacker EL, Emmerich B, Kotin RM, Hallek M. (1997) Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther 4:726-735
80. Tarte K, Zhang XG, Legouffe E, Hertog C, Mehtali M, Rossi JF, Klein B (1999) Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol 163:514-524
81. Dotti G, Savoldo B, Yotnda P, Rill DR (2000) Transgenic expression of CD40L produces an antitumor immune response to both CD40 positive and negative multiple myeloma. Blood 96:3620
82. Stevenson FK, Link CJ, Traynor A, Yu H, Corr M (1999) DNA vaccination against multiple myeloma. Semin Hematol 36:38-42
83. Gorschlüter M, Ziske C, Glasmacher A, Schmidt-Wolf I (2001) Current clinical and laboratory strategies to augment the efficiency in multiple myeloma. Clin Cancer Res 7:2195-2204
84. Russell SJ, Dunbar CE (2001) Gene therapy approaches for multiple myeloma. Semin Hematol 38:268-275
85. Syrengelas AD, Chen TT, Levy R (1996) DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038-1041
86. Wierda WG, Kipps TJ (2000) Gene therapy of hematologic malignancies. Semin Oncol 27:502-511
87. Fielding AK, Russell SJ (1997) Gene therapy for B cell lymphomas. Cancer Surv 30:327-342
88. Buttgereit P, Schmidt-Wolf IGH (2002) Gene therapy of lymphoma. J Hematother Stem Cell Res 11:457-467